INTRODUCTION
Multifocal breast cancer (MFBC) is commonly defined as multiple ipsilateral cancers (2 or more cancers in the same quadrant) and is related to but is different from multicentric breast cancer (MCBC), which is 2 or more cancers in different quadrants. [1] [2] [3] [4] [5] [6] [7] The incidence of MFBC is not fully known, with study estimates of breast cancer cases diagnosed as multifocal ranging from 6% to 77%. 1, [6] [7] [8] [9] A large study conducted by Yerushalmi et al 9 that evaluated differential outcomes in women with MFBC or MCBC (n 5 25,320) estimated the incidence of MFBC/MCBC within their cohort at 6.1%. MFBC is usually detected through imaging, particularly magnetic resonance imaging, and the identification of MFBC might alter clinical management. 1 Furthermore, prior studies suggest worse survival among patients with MFBC versus unifocal breast cancer. [1] [2] [3] 6, 7, 10 However, the epidemiology and biology of MFBC remain poorly understood without clearly identified risk factors or specific etiologies.
Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH), benign epithelial proliferations arising from the terminal duct lobular unit, have long been considered risk factors for the later development of breast cancer, with a nearly 4-fold average increased risk. [11] [12] [13] [14] [15] [16] [17] [18] Incidence and prevalence rates are difficult to establish because these diseases are not inherently dangerous and in historic studies have varied with socioeconomic status. 19 Both ADH and ALH are often considered markers of tissue instability, with an increased incidence of breast cancer during the immediate decade after the diagnosis. [14] [15] [16] [17] [18] 20 Prior studies have demonstrated an association between these benign proliferative breast diseases with atypia (PBDAs) and breast cancer, and other studies have associated MFBC with a poorer prognosis in comparison with unifocal breast cancer. 2, 6, 9, [11] [12] [13] [14] To our knowledge, although many studies have confirmed the relation between PBDA and cancer risk, none have reported on the risk of MFBC among women with a history of PBDA.
Two prevailing complementary theories exist that support the potential for a relation between PBDA and MFBC. The first theory implicates cellular progression in the development of breast cancer, whereby changes that lead to high-risk benign lesions, such as ADH, are indicators of genomic and cellular instability that, when left untreated, may lead to the development of invasive breast cancer. [21] [22] [23] [24] [25] The other prevailing theory is related to a field effect, in which environmental or cellular disturbances cause epigenetic changes and subsequent cellular and genomic instability to be present throughout the breast tissue. 26 This environment becomes favorable for multiple tumors to arise. 26 Moreover, multiple studies have shown that normal adjacent tissues are in fact abnormal 26 ; Yan et al 27 reported measurable methylation changes in breast tissue up to 4 cm away from excised tumors.
To further assess the association between PBDA and MFBC, we tested the hypothesis that among women with a breast cancer diagnosis, those with a history of PBDA would be at increased risk for MFBC in comparison with those without a history of PBDA. If such an association exists, then these women could be identified as potentially having an increased risk of a greater disease burden and poorer outcomes at the time of their breast cancer diagnosis. Women with a history of PBDA might benefit from additional clinical workup during the preoperative period, including breast magnetic resonance imaging.
MATERIALS AND METHODS

Data Source
We identified women from the New Hampshire Mammography Network (NHMN) with an incident breast cancer diagnosis during the time period from January 1, 2004 to December 31, 2014. Briefly, the NHMN is a prospective, longitudinal, state-based mammography registry initiated in 1996 that includes more than 225,000 women, residing almost exclusively within the New England region, who have presented for breast imaging at participating radiology facilities within the state of New Hampshire. 28 The NHMN records breast imaging findings with a linkage to detailed breast pathology information. Women's characteristics, including their sociodemographics, family history of breast cancer, and other risk factors (menopausal status, hormone replacement therapy use, and breast density), are collected through a self-administered questionnaire and a face-to-face interview conducted by a radiology technologist. 28 Pathology reports, submitted to the NHMN by participating New Hampshire pathology labs, have been abstracted into NHMN's data systems by a trained abstractor since 1995, and this enabled us to include benign findings for up to 19 years preceding a woman's cancer diagnosis.
Our cohort of 3944 consenting NHMN women with an incident breast cancer (invasive or in situ) 28, 29 diagnosed during the study period included only women older than 18 years. We excluded 371 women with a previous history of breast cancer recorded by the radiology technologist and 6 women for whom the cancer laterality was unknown; this left a final cohort of 3567 women. This study was Health Insurance Portability and Accountability Act-compliant and was approved by the Dartmouth College Committee for Protection of Human Subjects.
Variables of Interest
Our primary outcome of interest was MFBC. MFBC was defined as the explicit finding of multifocal disease (invasive carcinoma and/or ductal carcinoma in situ [DCIS]) on the pathology report at the time of the breast cancer diagnosis or during the follow-up treatment.
The main exposure was the occurrence or nonoccurrence of PBDA (ADH or ALH) before the woman's breast cancer diagnosis. To control for the potential influence of other types of benign breast disease (BBD), we categorized a history of other BBD as a set of 3 indicator variables (ever reported vs never reported): 1) nonproliferative BBD (including cysts, apocrine metaplasia, and fibroadenoma), 2) proliferative BBD without atypia (including single or multiple papilloma/papillary lesions, ductal hyperplasia, lobular hyperplasia, and radial scar/complex sclerosing lesions), or 3) no benign breast lesions before the breast cancer diagnosis. The BBD categories were not mutually exclusive because some women had BBD diagnoses from at least 2 BBD categories during the time period in which data were collected. Latency was defined as the time from the occurrence of the first BBD diagnosis to, but not including, the woman's breast cancer diagnosis and was classified into quartiles.
Women's breast cancer risk factors included the following: age at the breast cancer diagnosis (grouped as <50, 50-59, 60-69, or 70 years), breast density (categorized with the Breast Imaging Reporting and Data System criteria 30 ), family history of breast cancer, hormone replacement therapy use, and menopausal status. The laterality of BBD (grouped as no BBD, ipsilateral BBD, contralateral BBD, or both) was defined in relation to the laterality of the breast cancer. Lobular carcinoma in situ (LCIS) preceding the breast cancer diagnosis, the breast cancer type (invasive vs DCIS), and the nodal status (negative, positive, or not examined) were ascertained from pathology reports by a trained abstractor and were included in our analysis.
Statistical Analysis
Frequency distributions were reported, and chi-square tests were used to assess associations between BBD, laterality, latency, cancer type, nodal status, and women's breast cancer risk factors (age at diagnosis, menopausal status, breast density, hormone replacement therapy use, and family history of breast cancer) with and without PBDA and by the MFBC status.
A multivariate logistic regression model was used to assess the effect of prior PBDA on MFBC. The model was adjusted for the following: each of the 4 BBD categories as an indicator variable (ever reported vs never reported), BBD laterality, latency quartile, cancer type, nodal status, and women's breast cancer risk factors. The results are reported as odds ratios (ORs) and 95% confidence intervals (CIs). Analyses were performed with SAS 9.4 software (SAS 9.4 System Options: Reference, fourth edition; SAS Institute, Inc, Cary, North Carolina). A sensitivity analysis excluding women diagnosed with their first BBD less than 12 months before the first cancer diagnosis (n 5 3435) was completed with adjustments for the same factors used in our primary analysis. Additional sensitivity analyses included 1) adjustments for each woman's highest BBD diagnosis only instead of all categories diagnosed and 2) stratification by the DCIS/invasive breast cancer diagnosis.
RESULTS
Overall, among the 3567 women, the median age at the breast cancer diagnosis was 60 years (interquartile range, 51-69 years); 16.4% of the women in our cohort (n 5 586) had a history of any BBD, whereas 3.2% (n 5 113) had a history of PBDA ( Table 1 ). The median for the BBD latency period was 57 months (interquartile range, 19-103 months). Among the 586 women with a history of BBD, PBDA was associated with ipsilateral cancer risk (71.7% vs 54.3%; P < .0001) and a shorter latency period (cancer diagnosis occurring within 57 months of the first report of BBD, 61.0% vs 46.6%; P < .0001). Women presenting with PBDA tended to be younger (age < 50 years, 40.7% vs 20.5%; P < .0001), were more likely to have dense breasts (66.4% vs 52.6%; P 5 0.04), and were more likely to have received a diagnosis of DCIS (55.7% vs 26.2%; P < 0.0001) in comparison with women without PBDA ( Figure 1 , and the results are shown in Supporting Table 1 (see online supporting  information) .
Sensitivity analyses indicated effect sizes for PBDA similar to those found in the primary analysis. When they were restricted to the women diagnosed with breast cancer at least 12 months after their first BBD diagnosis, PBDA was associated with an adjusted OR of 2.85 (95% CI, 1.27-6.39). Similarly, controlling only for the highest form of BBD resulted in a PBDA-associated adjusted OR of 1.97. Stratifying by DCIS and the invasive cancer type resulted in PBDA-associated adjusted ORs of 2.19 and 1.88, respectively. In the sensitivity analyses, we found nonsignificant CIs for the highest form of BBD and stratification by cancer type because of the attenuated sample sizes.
DISCUSSION
Previous work has demonstrated that women with a history of ADH or ALH are at increased risk for developing breast cancer. [11] [12] [13] [14] [15] [16] [17] [18] However, to our knowledge, no study has reported on the risk of MFBC with respect to a prior history of PBDA. [1] [2] [3] [4] [5] [6] [7] [8] 10 Our results demonstrate that in a cohort of women with breast cancer, those with a history of PBDA are more likely to present with MFBC than women with no history of PBDA. We believe that this study is the first to demonstrate a relation between PBDA Original Article and MFBC and, if validated, has the potential to change clinical practice.
Over the past 40 years, various cohort and nested case-control studies have demonstrated an association between certain types of BBD, particularly atypical proliferative disease, and an increased risk of future breast cancer. [11] [12] [13] [14] 17, 18, 20, 31 Morphologic and molecular studies suggest continuous progressions of ADH ! DCIS ! invasive ductal carcinoma and ALH ! LCIS ! invasive lobular carcinoma, with distinct pathways containing characteristic molecular and cytogenetic alterations. Our results are not counter to this theory because 71.7% of the women with PBDA had ipsilateral breast cancer and 11.5% had breast cancer on both sides, whereas 54.3% of the women with BBD without atypia had ipsilateral breast cancer and 5.5% had breast cancer on both sides. One 
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Cancer April 1, 2018 molecular pathway supporting the progression hypothesis is a low-grade neoplastic pathway that commonly contains a loss of function of genes located on chromosome 16q and a gain of function of genes located on 1q. 32 These breast cancers typically progress from ADH through lownuclear grade DCIS to low-grade invasive carcinomas, and they are often associated with lobular neoplasia. In contrast, a high-grade neoplastic pathway is associated with an increased number of genetic alterations, including P53 mutations, is often negative for hormone receptors, and is frequently positive for either Her-2 or basal markers. 33 Other literature implicates the field effect, whereby the entire cellular region has been destabilized by genetic or environmental effects. 26, 27 Similarly, the field effect theory is a plausible explanation for our findings, although we cannot speculate further on which theory is more credible because we did not assess molecular markers. Suggestive evidence is found in the slightly higher incidence of breast cancer in the breast contralateral to the initial PBDA (7.1% with MFBC vs 5.8% without MFBC). Women with a history of PBDA who were diagnosed with MFBC also had a higher rate of cancer in both breasts (1.6%) in comparison with women with PBDA but no finding of MFBC (1.0%). Our findings are clinical in nature and are not biologically validated; additional studies are required to further understand the molecular mechanisms linking PBDA and MFBC. Our study was underpowered to detect an association between LCIS and MFBC (OR, 2.81; 95% CI, 0.52-14.92). 10, 34, 35 The study contained only 15 women with a prior diagnosis of LCIS, and 2 of these women were confirmed to have MFBC. Notably, 7 of the women with prior LCIS also had at least 1 diagnosis of PBDA (6.19% of the women with PBDA), whereas 8 women without a diagnosis of PBDA did (0.23% of the women without PBDA). Of the 7 women with prior LCIS and PBDA diagnoses, 5 were diagnosed with PBDA before LCIS; the other 2 cases were concurrently diagnosed. The effect size associated with the relation between LCIS and MFBC, though not statistically significant, was similar to the effect size found between DCIS and invasive breast cancer. We were unable to further examine the relation between PBDA and LCIS because of the limitations of the sample size, but we consider this a relevant area for future work.
Our findings have potential clinical importance for women with newly diagnosed breast cancer. The preoperative evaluation after a breast cancer diagnosis is used to determine the extent of disease for accurate staging and to plan surgical management; however, current practice is highly variable across institutions. 36 The preoperative evaluation might include multiple breast imaging modalities, which can result in additional biopsies. Breast magnetic resonance imaging has increasingly been used preoperatively during the past 10 years because of its high sensitivity for detecting additional lesions and its negative predictive value. 37, 38 Although the use of breast magnetic resonance imaging for staging after a breast cancer diagnosis is controversial, 37, 38 for women with an increased likelihood of MFBC, it might be an important and appropriate component of preoperative management.
BBD has consistently been linked to a higher cancer risk. [11] [12] [13] [14] [15] [16] [17] [18] Previous studies have demonstrated that the use of adjuvant therapies in women with a history of PBDA reduces the risk of DCIS, LCIS, and invasive cancer occurrences. 39 Our work demonstrates that women with PBDA are more likely to develop MFBC. In light of these findings, additional recommendations for women with a history of PBDA to use modified cancer screening schedules or adjuvant therapies could be considered. 39 The strengths of this study include the large population-based cohort of breast cancer cases and substantial longitudinal follow-up with pathology and cancer outcomes. The longitudinal registry data and detailed abstracted pathology data give us the unique ability to ascertain specific types of BBD and record MFBC. Cancers identified within the 11-year study period may be linked to benign findings preceding the cancer diagnosis by up to 19 years because of the duration of the registry data. Limitations include the racial composition of the women (98% white), which is representative of the upper New England region population. In addition, because the presence of MFBC was recorded only if there was an explicit indication of multifocal disease stated in the pathology report, the data may underestimate the incidence of MFBC. Another limitation of this study is the lack of MCBC in our database. MCBC cases are included in the reference group with unifocal cases, and thus the true effect size is likely attenuated because of the heterogeneity of the reference group. Finally, diagnoses were obtained from pathology reports; a central pathology review of slides by a trained breast pathologist to confirm diagnoses was not able to be conducted. Therefore, the possibility of misclassification and bias of the results toward the null exists.
In summary, we found a significant association between a history of PBDA and the subsequent risk of MFBC in a cohort of women diagnosed with breast cancer. Women with a PBDA diagnosis preceding a breast cancer diagnosis could potentially benefit from an additional preoperative evaluation to better assess their risk and determine appropriate treatment strategies.
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